192 related articles for article (PubMed ID: 29710299)
1. Concerns About the Approval of Nusinersen Sodium by the US Food and Drug Administration.
Gerrity MS; Prasad V; Obley AJ
JAMA Intern Med; 2018 Jun; 178(6):743-744. PubMed ID: 29710299
[No Abstract] [Full Text] [Related]
2. Expanded Access for Nusinersen in Patients With Spinal Muscular Atropy: Negotiating Limited Data, Limited Alternative Treatments, and Limited Hospital Resources.
Wilfond BS; Morales C; Taylor HA
Am J Bioeth; 2017 Oct; 17(10):66-67. PubMed ID: 29020560
[No Abstract] [Full Text] [Related]
3. Nusinersen for Type 1 Spinal Muscular Atrophy: A Father's Perspective.
Hoot NR
Pediatrics; 2019 Oct; 144(4):. PubMed ID: 31506303
[No Abstract] [Full Text] [Related]
4. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides.
Aartsma-Rus A
Nucleic Acid Ther; 2017 Apr; 27(2):67-69. PubMed ID: 28346110
[No Abstract] [Full Text] [Related]
5. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
[No Abstract] [Full Text] [Related]
6. Spinal muscular atrophy 5Q - Treatment with nusinersen.
; Silvinato A; Bernardo WM
Rev Assoc Med Bras (1992); 2018 Jun; 64(6):484-491. PubMed ID: 30304304
[TBL] [Abstract][Full Text] [Related]
7. Is There a 'Right to Try' Experimental Therapies? Ethical Criteria for Selecting Patients With Spinal Muscular Atrophy to Receive Nusinersen in an Expanded Access Program.
Jecker NS
Am J Bioeth; 2017 Oct; 17(10):70-71. PubMed ID: 29020544
[No Abstract] [Full Text] [Related]
8. Resolution of skin necrosis after nusinersen treatment in an infant with spinal muscular atrophy.
Salmin F; Albamonte E; Morettini V; Gagliano N; Mercuri E; Sansone VA
Muscle Nerve; 2019 Jun; 59(6):E42-E44. PubMed ID: 30811610
[No Abstract] [Full Text] [Related]
9. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
[TBL] [Abstract][Full Text] [Related]
10. Putting our best foot forward: Clinical, treatment-based and ethical considerations of nusinersen therapy in Canada for spinal muscular atrophy.
Vukovic S; McAdam L; Zlotnik-Shaul R; Amin R
J Paediatr Child Health; 2019 Jan; 55(1):18-24. PubMed ID: 30246272
[TBL] [Abstract][Full Text] [Related]
11. Ethical Challenges Confronted When Providing Nusinersen Treatment for Spinal Muscular Atrophy.
Burgart AM; Magnus D; Tabor HK; Paquette ED; Frader J; Glover JJ; Jackson BM; Harrison CH; Urion DK; Graham RJ; Brandsema JF; Feudtner C
JAMA Pediatr; 2018 Feb; 172(2):188-192. PubMed ID: 29228163
[TBL] [Abstract][Full Text] [Related]
12. Effect of Nusinersen on Respiratory Muscle Function in Different Subtypes of Type 1 Spinal Muscular Atrophy.
LoMauro A; Mastella C; Alberti K; Masson R; Aliverti A; Baranello G
Am J Respir Crit Care Med; 2019 Dec; 200(12):1547-1550. PubMed ID: 31433957
[No Abstract] [Full Text] [Related]
13. [Spinal muscular atrophy treated with nusinersen].
Boesen MS; Albrechtsen S; Born AP
Ugeskr Laeger; 2019 Jan; 181(2):. PubMed ID: 30618374
[TBL] [Abstract][Full Text] [Related]
14. Nusinersen improved respiratory function in spinal muscular atrophy type 2.
Tanaka R; Fukushima F; Motoyama K; Kobayashi C; Izumi I
Pediatr Int; 2021 Aug; 63(8):973-974. PubMed ID: 34245199
[No Abstract] [Full Text] [Related]
15. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
[TBL] [Abstract][Full Text] [Related]
16. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
Mercuri E; Darras BT; Chiriboga CA; Day JW; Campbell C; Connolly AM; Iannaccone ST; Kirschner J; Kuntz NL; Saito K; Shieh PB; Tulinius M; Mazzone ES; Montes J; Bishop KM; Yang Q; Foster R; Gheuens S; Bennett CF; Farwell W; Schneider E; De Vivo DC; Finkel RS;
N Engl J Med; 2018 Feb; 378(7):625-635. PubMed ID: 29443664
[TBL] [Abstract][Full Text] [Related]
17. Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience.
Messina S; Pane M; Sansone V; Bruno C; Catteruccia M; Vita G; Palermo C; Albamonte E; Pedemonte M; Bertini E; Binetti L; Mercuri E;
Neuromuscul Disord; 2017 Dec; 27(12):1084-1086. PubMed ID: 29132728
[No Abstract] [Full Text] [Related]
18. Nusinersen in spinal muscular atrophy type 1 from neonates to young adult: 1-year data from three Asia-Pacific regions.
Chan SH; Chae JH; Chien YH; Ko TS; Lee JH; Lee YJ; Nam SO; Jong YJ
J Neurol Neurosurg Psychiatry; 2021 Nov; 92(11):1244-1246. PubMed ID: 33574081
[No Abstract] [Full Text] [Related]
19. Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen.
Winter B; Guenther R; Ludolph AC; Hermann A; Otto M; Wurster CD
J Neurol Neurosurg Psychiatry; 2019 Sep; 90(9):1068-1069. PubMed ID: 30630960
[No Abstract] [Full Text] [Related]
20. [Nusinersen in SMA children: evolution or revolution? - Clinical use of innovative, repurposed or off-label therapies: a real life experience (2)].
Richelme C
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():22-25. PubMed ID: 30943156
[No Abstract] [Full Text] [Related]
[Next] [New Search]
